|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 601 PENNSYLVANIA AVENUE, NW |
Address2 | SUITE 700 |
City | WASHINGTON, DC |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Franklin Lakes |
State | NJ |
Zip Code | 07417 |
Country | USA |
|
5. Senate ID# 89177-12
|
||||||||
|
6. House ID# 366750000
|
TYPE OF REPORT | 8. Year | 2008 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Peter Begans, Vice President, Federal Government Affairs |
Date | 01/16/2009 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Health Information Technology, Electronic Prescribing, Comparative Effectiveness, Confidentiality of Health Information, Generic Drugs, Generic Biologics, Carve-out of Generic Drugs from State Generic Substituion Laws
HR 971 and S 885 - Community Pharmacy Fairness Act of 2007; all aspects
HR 1432 and S. 316 - Preserve Access to Affordable Generics Act; all aspects
HR 1956 - Patient Protection and Innovative Biologic Medicines Act of 2007; all aspects
HR 2567 and S. 3505 and S 870 - Medicare Home Infusion Therapy Consolidated Coverage Act of 2008; all aspects
HR 2914 and S 2990 - Medicare IVIG Access Act of 2007; all aspects
HR 3800 - Promoting Health Information Technology Act; all aspects
HR 5629 - Pathway for Biosimilars Act; all aspects
HR 6357- Protecting Records, Optimizing Treatment and Easing Communcations through Healthcare Technology PRO(TECH)T Act of 2008; all aspects
HR 6898 - Health-e-Information Technology Act of 2008; all aspects
S 976 - Genomics and Personalized Medicine Act of 2007; all aspects
S 1408 - Health Information Technology Act of 2007; all aspects
S 1693 - Wired for Health Care Quality Act; all aspects
S 1695 - Biologics Price Competition and Innovation Act of 2007; all aspects
S. 1814 - Health Information Privacy and Security Act; all aspects
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Federal Trade Commission (FTC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Peter |
Begans |
|
|
|
Bill |
Head |
|
|
|
Kimberly |
Linthicum |
|
|
|
Allyson |
Blandford |
|
|
|
Heather |
Stewart |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicare Part D, Antitrust Exemption for Independent Pharmacies, IVIG Payments, Competitive Acquuisition Program for Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS)
HR 971 and S 885 - Community Pharmacy Fairness Act of 2007; all aspects
HR 2567 and S 3505 and S 870 - Medicare Home Infusion Therapy Consolidated Coverage Act of 2007; all aspects
HR 2914 and S 2990 - Medicare IVIG Access Act of 2008; all aspects
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Peter |
Begans |
|
|
|
Bill |
Head |
|
|
|
Kimberly |
Linthicum |
|
|
|
Allyson |
Blandford |
|
|
|
Heather |
Stewart |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Electronic Prescribing, Electronic Prescribing of Controlled Substances, Antitrust Exemption for Independent Pharmacies
HR 971 and S 885 - Community Pharmacy Fairness Act of 2007; all aspects
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Peter |
Begans |
|
|
|
Bill |
Head |
|
|
|
Kimberly |
Linthicum |
|
|
|
Allyson |
Blandford |
|
|
|
Heather |
Stewart |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |